|
|
News Breaks | | | | September 26, 2012 | | 07:58 EDT |  | BDSI | Reckitt Benckiser news positive for BioDelivery Sciences, says Ladenburg
Ladenburg views Reckitt Benckiser's plans to discontinue supply of Suboxone Tablets as positive for BioDelivery Sciences. The firm says Reckitt's plan to remove the tablet from the market is not the result of any safety issue with the components of Suboxone, and it believes the move will constrain the ability of generic tablets to grab market share. Ladenburg reiterates a Buy rating on BioDelivery Sciences with a $7.25 price target. | |
|
News For BDSI From The Last 14 Days Check below for free stories on BDSI the last two weeks. |
|
|
| June 10, 2013 | | 07:08 EDT |  | BDSI | BioDelivery Sciences announces MDA submission for Bunavail
 Subscribe for More Information | |
|
|
|
|
|
|
